日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials

多拉韦林治疗方案的疗效和安全性按性别和种族划分:三项3期临床试验的长期结果

Walmsley, Sharon L; Kumar, Princy N; Orkin, Chloe; Thompson, Melanie; Squires, Kathleen; Xu, Zhi Jin; Greaves, Wayne; Plank, Rebeca M; Whiteside, Yohance; Lahoulou, Rima

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial

多拉韦林/伊斯拉曲韦(100/0.75 毫克)每日一次与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为 HIV-1 初始治疗的比较:一项 3 期随机、对照、双盲、非劣效性试验的 48 周结果

Rockstroh, Jürgen K; Paredes, Roger; Cahn, Pedro; Molina, Jean-Michel; Sokhela, Simiso M; Hinestrosa, Federico; Kassim, Sheetal; Cunningham, Douglas; Ghosn, Jade; Bogner, Johannes R; Gatanaga, Hiroyuki; Asante-Appiah, Ernest; Zhang, Ying; Nwoke, Uchechukwu; Klopfer, Stephanie O; Eves, Karen; Squires, Kathleen; Correll, Todd; Fox, Michelle C; Pisculli, Mary L

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial

他莫昔芬对接受抗逆转录病毒治疗的女性中伏立诺他诱导的人类免疫缺陷病毒表达的影响:艾滋病临床试验组 A5366,MOXIE 试验

Scully, Eileen P; Aga, Evgenia; Tsibris, Athe; Archin, Nancie; Starr, Kate; Ma, Qing; Morse, Gene D; Squires, Kathleen E; Howell, Bonnie J; Wu, Guoxin; Hosey, Lara; Sieg, Scott F; Ehui, Lynsay; Giguel, Francoise; Coxen, Kendyll; Dobrowolski, Curtis; Gandhi, Monica; Deeks, Steve; Chomont, Nicolas; Connick, Elizabeth; Godfrey, Catherine; Karn, Jonathan; Kuritzkes, Daniel R; Bosch, Ronald J; Gandhi, Rajesh T

Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females

达匹韦林和安慰剂阴道环对青春期、哺乳期和绝经后女性肠道菌群的影响

Austin, Michele N; Meyn, Leslie A; Avolia, Hilary A; Petrina, Melinda A; Cosentino, Lisa A; Alphonse, Calins; Chen, Beatrice A; Bunge, Katherine; Noguchi, Lisa; Beigi, Richard; Squires, Kathleen; Hillier, Sharon L

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯 (TDF) 与依非韦伦/恩曲他滨/TDF 在初治 1 型人类免疫缺陷病毒感染成人中的疗效比较:随机、双盲、3 期 DRIVE-AHEAD 非劣效性试验第 96 周结果

Orkin, Chloe; Squires, Kathleen E; Molina, Jean-Michel; Sax, Paul E; Sussmann, Otto; Lin, Gina; Kumar, Sushma; Hanna, George J; Hwang, Carey; Martin, Elizabeth; Teppler, Hedy

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls

达匹韦林阴道环的使用对青春期女孩宫颈阴道免疫和功能性微生物组的影响

Farr Zuend, Christina; Noël-Romas, Laura; Hoger, Sarah; McCorriser, Stuart; Westmacott, Garrett; Marrazzo, Jeanne; Hillier, Sharon L; Dezzutti, Charlene; Squires, Kathleen; Bunge, Katherine E; Burgener, Adam

Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls

一项关于青少年女性对使用阴道环预防艾滋病毒感染的接受度和依从性的定性研究

Baker, Zoë; Javanbakht, Marjan; Moore, Janell; Brosnan, Hannah; Squires, Kathleen; Bunge, Katherine; Zimet, Gregory; Mensch, Barbara; Soto-Torres, Lydia; Kapogiannis, Bill; Levy, Lisa; Hoesley, Craig; Reirden, Daniel; Gaur, Aditya; Mayer, Kenneth; Futterman, Donna; Gorbach, Pamina

Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women

简报:含达匹韦林阴道环在青少年女性中的IIa期安全性研究

Bunge, Katherine E; Levy, Lisa; Szydlo, Daniel W; Zhang, Jingyang; Gaur, Aditya H; Reirden, Daniel; Mayer, Kenneth H; Futterman, Donna; Hoesley, Craig; Hillier, Sharon L; Marzinke, Mark A; Hendrix, Craig W; Gorbach, Pamina M; Wilson, Craig M; Soto-Torres, Lydia; Kapogiannis, Bill; Nel, Annalene; Squires, Kathleen E

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

在初治成人人类免疫缺陷病毒-1感染患者中,多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯不劣于依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯:DRIVE-AHEAD试验第48周结果

Orkin, Chloe; Squires, Kathleen E; Molina, Jean-Michel; Sax, Paul E; Wong, Wing-Wai; Sussmann, Otto; Kaplan, Richard; Lupinacci, Lisa; Rodgers, Anthony; Xu, Xia; Lin, Gina; Kumar, Sushma; Sklar, Peter; Nguyen, Bach-Yen; Hanna, George J; Hwang, Carey; Martin, Elizabeth A

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

拉替拉韦 1200 毫克每日一次与 400 毫克每日两次联合恩曲他滨和富马酸替诺福韦二吡呋酯治疗既往未接受治疗的 HIV-1 感染:ONCEMRK 随机、双盲、非劣效性试验第 96 周结果

Cahn, Pedro; Sax, Paul E; Squires, Kathleen; Molina, Jean-Michel; Ratanasuwan, Winai; Rassool, Mohammed; Bloch, Mark; Xu, Xia; Zhou, Yan; Homony, Brenda; Hepler, Deborah; Teppler, Hedy; Hanna, George J; Nguyen, Bach-Yen; Greaves, Wayne